ELYM News

In the typically-slow month of August, nine IPOs raised $1.0 billion, joined by 31 SPACs. Only four of the nine offerings raised over $100 million. Activity was well below August 2020, which saw investors and bankers skip their vacations due to the pandemic. Five listings also postponed this past month amid poor IPO aftermarket returns and “IPO indigestion” after summer...read more

The summer IPO market is wrapping up, and while we could see a few more launches, this past week’s two deals should be some of the last IPOs before fall. SPAC activity continued to bounce back, with 17 blank check IPOs during the week. After slashing its range, holdover Eliem Therapeutics (ELYM) raised $80 million at a $344 million market cap. Its lead...read more

Eliem Therapeutics, a Phase 2a biotech developing therapies for neuronal excitability disorders, raised $80 million by offering 6.4 million shares at $12.50, as expected. The company offered 0.4 million more shares than anticipated. It originally planned to offer 4.5 million shares at a range of $17 to $19, before revising the terms on Monday. Eliem is focused on developing...read more

Eliem Therapeutics, a Phase 2a biotech developing therapies for neuronal excitability disorders, lowered the proposed deal size for its upcoming IPO on Monday. The Redmond, WA-based company now plans to raise $75 million by offering 6 million shares at $12.50. The company had previously filed to offer 4.5 million shares at a range of $17 to $19. At the revised deal size, Eliem...read more